Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Telbivudine exerts no antiviral activity against HIV-1 in vitro and in humans.

Antiviral therapy - 1 Jan 2011

van Maarseveen Noortje M, Wensing Annemarie Mj, de Jong Dorien, Beilhartz Greg L, Obikhod Aleksandr, Tao Sijia, Pingen Marieke, Arends Joop E, Hoepelman Andy Im, Schinazi Raymond F, Götte Matthias, Nijhuis Monique

Abstract excerpt

BACKGROUND: HIV-HBV-coinfected individuals who need to be treated only for their HBV infection have limited therapeutic options, since most approved anti-HBV agents have a risk of selecting for drug-resistant HIV mutants. In vivo data are inconclusive as to whether telbivudine (LdT) may exert antiviral effects against HIV. Thus, we investigated in further detail the antiviral activity and the biochemical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CD4 Lymphocyte Count
Share to Coinfection

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis B, Chronic

Share to Hepatitis B virus

Share to Nucleosides

Share to Pyrimidinones

Share to Thymidine

Share to Viral Load

Source

Open in PubMed Open full text

Identifiers

PMID: 22024528
DOI: 10.3851/IMP1912
PMCID: PMC7732022

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Telbivudine exerts no antiviral activity against HIV-1 in vitro and in humans.PMID 22024528Read ↗

Virology and clinical sequelae of drug-resistant HBV in HIV-HBV-coinfected patients on highly active antiretroviral therapy.Semantic proximity Read ↗

Hepatitis B virus drug resistance in HIV-1-infected patients taking lamivudine-containing antiretroviral therapy.Semantic proximity Read ↗

Low risk of lamivudine-resistant HBV and hepatic flares in treated HIV-HBV-coinfected patients from Côte d'Ivoire.Semantic proximity Read ↗

Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy.Semantic proximity Read ↗

Prevalence and characterization of lamivudine-resistant hepatitis B virus mutations in HIV-HBV co-infected individuals.Semantic proximity Read ↗

Telbivudine versus lamivudine in patients with chronic hepatitis B.Semantic proximity Read ↗

Prolonged use of tenofovir in HIV/hepatitis B virus (HBV)-coinfected individuals does not lead to HBV polymerase mutations and is associated with persistence of lamivudine HBV polymerase mutations.Semantic proximity Read ↗

HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons.Semantic proximity Read ↗

Clinical implications of lamivudine resistance by HBV.Semantic proximity Read ↗

Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine.Semantic proximity Read ↗

Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir.Semantic proximity Read ↗

Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.